About Epitomics
Epitomics is a Healthcare company based in Burlingame (United States) founded in 2001 by Weimin Zhu and Guo Liang Yu, and was acquired by Abcam in March 2012. Monoclonal antibody technology and products are developed by Epitomics. Epitomics has raised $16.21 million across 3 funding rounds from investors including Abcam, Sycamore Ventures and Amkey Ventures. Its chief executive, as recorded, is Guo Liang Yu. Epitomics offers products and services including Primary Antibodies, ELISA Kits, and Cell Lines. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Proteomics. Its legal entity is Abcam Limited. Its competitors include GenScript, Vector Laboratories and Allele Biotech; 2 of its 3 listed competitors have raised funding.
Company details
Epitomics is a biotechnology focussed on developing MAb technology and products. It developed rabbit MAb technology RabMAb for the creation of specific and custom rabbit MAbs that has potential in new MAb therapies. It claims that the MAbs produced from the technology acted as challenging targets such as splice variants, point mutations, species-specific orthologs, post-translational modifications, and small molecule compounds and has benefitted more than 550 institutions and 150 pharma and biotech companies. In March 2012, Abcam acquired Epitomics and since then working as its subsidiary.
- Headquarters Burlingame, United States
- Founders Weimin Zhu, Guo Liang Yu
- Stage Acquired
- SectorsHealthcare
- Website epitomics.com
- Social LinkedIn YouTube
- Acquired by Abcam (Mar 2012)
- Legal Name Abcam Limited
Products & Services of Epitomics
Epitomics offers a comprehensive portfolio of products and services, including Primary Antibodies, ELISA Kits, and Cell Lines.
High-specificity antibodies for detecting proteins in experiments.
Kits for sensitive immunoassay detection of various targets.
Validated cell lines for gene-editing and research applications.
Apps and channels of Epitomics
its YouTube channel Abcam has 2.43K subscribers and 30 videos.
Videos from Epitomics
The most watched videos on Epitomics's YouTube channel, Abcam (2.43K subscribers). Click a video to play it here.
More on Abcam.
Funding Insights of Epitomics
Epitomics has successfully raised a total of $16.21M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $2.11 million completed in January 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16.21M
- Total Rounds 3
- Last Round Series C β $2.11M
- First Round $3.1M
(Mar 2003)
- Investors Count 3
All 3 funding rounds of Epitomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2009 | $2.11M | Series C | β | β | β |
| Apr 2004 | $11M | Series C | β | β | |
| Mar 2003 | $3.1M | Series B | β | β |
4 investors in total: 4 institutional.
Investors in Epitomics
Epitomics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Abcam, Sycamore Ventures and Amkey Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| sycaventures.com | ||||
| amkeyvc.com | ||||
| kensonventures.com | ||||
Biological reagents and antibodies are developed for life science research. | 1998 | abcam.com | Cambridge, United Kingdom |
Investor details for Epitomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Epitomics
2 people are tracked at Epitomics (2 in leadership).
| Name | Role | Group |
|---|---|---|
Weimin Zhu | Co-Founder | Leadership |
Guo Liang Yu | Co-Founder & CEO | Leadership |
Complete people profiles for Epitomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Epitomics
5 dated milestones of Epitomics across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Epitomics is founded.
- Funding First funding round of $3.1M.
- Funding Latest funding round, Series C, of $2.1M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Abcam.
Competitors of Epitomics
Epitomics has 3 listed competitors in our database, 2 of them funded. They include GenScript, Vector Laboratories and Allele Biotech.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| vectorlabs.com | 1976 | Burlingame, United States | Labeling and detection reagents immunohistochemistry studies and other life science research applications | |||
| allelebiotech.com | 1999 | San Diego, United States | $18M | Nano-antibodies, iPSCs, fluorescent proteins, and RNAi are developed. |
Detailed competitors of Epitomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Epitomics
Websites that share an audience with Epitomics (epitomics.com).
Websites whose visitors overlap most with Epitomics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| everestbiotech.com | 100% | 1.6K | #10,518,665 | View details | |
| abgent.com | 92% | View details | |||
| bioworlde.com | 90% | #4,508,617 | View details | ||
| fusionantibodies.com | 89% | View details | |||
| abnova.com | 88% | 30.7K | #957,320 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 24 similar websites and full traffic analytics for Epitomics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 24 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Epitomics (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Epitomics
Complete news archive for Epitomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Epitomics
Epitomics was founded in 2001 and raised its 1st funding round 2 years after it was founded.
Epitomics is headquartered in Burlingame, United States. It is registered at Burlingame, California, United States.
Guo Liang Yu is the CEO of Epitomics, as recorded in our data. They have also founded this company.
Epitomics is a funded company, having raised a total of $16.21M across 3 funding rounds to date. The company's 1st funding round was a Series B of $3.1M, raised on Mar 2003.
Epitomics is a biotechnology focussed on developing MAb technology and products. It developed rabbit MAb technology RabMAb for the creation of specific and custom rabbit MAbs that has potential in new MAb therapies. It claims that the MAbs produced from the technology acted as challenging targets such as splice variants, point mutations, species-specific orthologs, post-translational modifications, and small molecule compounds and has benefitted more than 550 institutions and 150 pharma and biotech companies. In March 2012, Abcam acquired Epitomics and since then working as its subsidiary.
Epitomics's top competitors include GenScript, Vector Laboratories and Allele Biotech.
Epitomics offers Primary Antibodies, ELISA Kits, and Cell Lines.
Epitomics has 4 investors. Key investors include Abcam, Sycamore Ventures, Amkey Ventures, and Kenson Ventures.
Epitomics operates through Abcam Limited.
Yes. Epitomics was acquired by Abcam in March 2012.

